Skip to main content

European vaccine effort against HIV/AIDS - III

Objective

A vaccine against HIV-1/AIDS is urgently needed to slow down the current epidemic in both Africa and Asia. The predominant subtype of HIV-1 causing the AIDS epidemic in Africa and Asia is subtype C. Clinical lots of priming agents - Gemlike Forest virus (SFV) and naked DNA -, as well as a boosting agent - the attenuated poxvirus strain NYV AC -, are prepared; all vaccine components are derived from HIV-1 subtype C and include the gag, poll, net and envy genes. The objective of the Euro Vac-III demonstration project is to identify the best priming agent, DNA vs. SFV, that allows for reduction of the NYVAC dose without significant loss of immunogenicity. This demonstration project aims for the establishment of the most immunogenic vaccine that is suitable for mass vaccination and forms the last step towards moving into phase IIb and III efficacy trials.

Funding Scheme

DEM - Demonstration contracts

Coordinator

KAROLINSKA INSTITUTE
Address
13,Nobels Väg 16
171 77 Stockholm
Sweden

Participants (8)

ACADEMISCH ZIEKENHUIS BIJ DE UNIVERSITEIT VAN AMSTERDAM
Netherlands
Address
Meibergdreef 15
1105AZ Amsterdam
AVENTIS PASTEUR SA
France
Address
1541,Avenue Marcel Mérieux 1541
69280 Marcy-l'etoile
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Spain
Address
Campus De La Universidad Autonoma De Madrid
28049 Madrid
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
United Kingdom
Address
Du Cane Road
W12 0NN London
MEDICAL RESEARCH COUNCIL
United Kingdom
Address
Euston Road, 222
W1N 4AL London
MUNICIPAL HEALTH SERVICE
Netherlands
Address
Nieuwe Achtergracht 100
1018 WT Amsterdam
UNIVERSITAET REGENSBURG
Germany
Address
11,Frans-joseph-strauss-allee 11
93053 Regensburg
UNIVERSITY OF LAUSANE
Switzerland
Address
Avenue De Beaumont 29 Hopital Beaumont
1011 Lausanne